NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
3.500
-0.490 (-12.28%)
At close: Jun 27, 2025, 4:00 PM
3.680
+0.180 (5.14%)
After-hours: Jun 27, 2025, 4:04 PM EDT
Company Description
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors.
The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.
NeOnc Technologies Holdings, Inc.
Country | United States |
Founded | 2008 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Thomas Chen |
Contact Details
Address: 23975 Park Sorrento, Suite 205 Calabasas, California 91302 United States | |
Phone | 310-663-7831 |
Website | neonctech.com |
Stock Details
Ticker Symbol | NTHI |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001979414 |
ISIN Number | US64051A1016 |
Employer ID | 92-1954864 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Executive Officer, Chief Scientific Officer and Director |
Keithly A. Garnett | Chief Financial Officer and Director |
Amir Farrokh Heshmatpour | President, Executive Chairman and Secretary |
Dr. Josh Neman-Ebrahim M.D. | Chief Clinical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 16, 2025 | EFFECT | Notice of Effectiveness |
Jun 16, 2025 | 424B5 | Filing |
Jun 12, 2025 | 8-K | Current Report |
Jun 6, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Jun 6, 2025 | 8-K | Current Report |
Jun 3, 2025 | 8-K | Current Report |
May 9, 2025 | 10-Q | Quarterly Report |
May 6, 2025 | EFFECT | Notice of Effectiveness |
May 6, 2025 | 424B5 | Filing |
May 2, 2025 | UPLOAD | Filing |